Risk of hypertension in cancer patients treated with sorafenib: an updated systematic review and meta-analysis
Por: T Funakoshi, A Latif y M D Galsky. Journal of Human Hypertension (2013) 27, 601–611.
Sorafenib, a multi-kinase inhibitor, has been reported to be associated with hypertension (HTN). However, the risk of severe HTN with sorafenib treatment has not been well described. We performed an up-to-date meta
-analysis of high-grade HTN in cancer patients treated with sorafenib. Medline databases and the American Society of Clinical Oncology online database of meeting abstracts were searched up to August 2012 for
relevant clinical trials. Eligible studies included phase II and III trials of sorafenib in patients with any type of cancer describing events of HTN according to the Common Terminology Criteria for Adverse Events. The summary incidence, relative risk (RR), and 95% confidence intervals (CIs) were calculated.
[Actualizado: 30 de septiembre 2013]
Comentarios recientes